$0.37 -$0.03 (-7.4%)

04:00 PM EDT on 10/17/19

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 2 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Current Price $0.37 Mkt Cap $12.52
Open $0.42 P/E Ratio 0.00
Prev. Close $0.40 Div. (Yield) $0.00 (0.0%)
Daily Range $0.37 - $0.42 Volume 50,051
52-Wk Range $0.28 - $1.18 Avg. Daily Vol.

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

75 Outperform
11 Underperform
 

All-Star Players

4 Outperform
4 Underperform
 

Wall Street

3 Outperform
0 Underperform
 

Top NASDAQ:CYCC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.81)
Submitted January 03, 2016

My God, is the SEAMLESS trial still running? This pointless excursion began all the way back at the beginning of 2011 and is still lumbering along despite failing an interim futility analysis in December 2014. That's right! The trial already failed.… More

zzlangerhans (99.81)
Submitted February 19, 2015

In the last few months, lots of weak biopharmas took huge hits on negative catalysts and their share prices seemed to gravitate towards the 50 cent level with market caps at about half of cash on hand. I owned substantial chunks of almost all of them… More

NASDAQ:CYCC VS S&P 500 (SPY)

Fools bullish on NASDAQ:CYCC are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about CYCC.

Recs

0
Member Avatar oscillation (68.59) Submitted: 6/1/2015 1:40:33 AM : Outperform Start Price: $8.64 NASDAQ:CYCC Score: -136.85

nev

Recs

0
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $44.94 NASDAQ:CYCC Score: -163.16

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

0
Member Avatar toegar2000 (47.16) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $64.19 NASDAQ:CYCC Score: -196.53

Looks good IMO

Leaderboard

Find the members with the highest scoring picks in CYCC.

Score Leader

longtermgrowth09

longtermgrowth09 (< 20) Score: +265.67

The Score Leader is the player with the highest score across all their picks in CYCC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
longtermgrowth09 < 20 8/3/2010 Underperform 5Y $137.26 -99.73% +165.94% +265.67 0 Comment
mrtofoo 24.11 1/7/2008 Underperform 5Y $425.66 -99.91% +121.44% +221.35 0 Comment
MFBurritoSquat 92.61 8/29/2012 11/28/2012 Underperform 1Y $37.47 -99.01% +111.37% +210.38 0 Comment
bluebare 41.06 12/7/2012 Underperform 5Y $75.63 -99.51% +110.63% +210.14 0 Comment
imrhh < 20 5/7/2007 Underperform 3M $637.27 -99.94% +109.60% +209.54 2 Comments
klaracat 29.79 10/22/2012 Underperform 5Y $60.93 -99.39% +108.96% +208.35 0 Comment
GenericMind5885 99.67 2/27/2015 Underperform 5Y $17.97 -97.94% +41.61% +139.55 0 Comment
IdahoInvestor 41.47 8/13/2015 Underperform 5Y $7.18 -94.84% +43.31% +138.15 0 Comment
zzlangerhans 99.81 8/22/2016 Underperform 1Y $8.75 -95.76% +36.88% +132.64 0 Comment
iPittytheFool 69.01 10/10/2016 Underperform 5Y $5.47 -93.22% +38.39% +131.61 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCollinsStew 69.90 4/19/2010 Outperform NS $213.24 -99.83% +151.35% -251.17 0 Comment
TrackNeedham 89.98 6/4/2007 Outperform NS $798.00 -84.74% -13.46% -71.27 3/31/2011 @ $121.80 0 Comment
TrackLazardCapit 21.08 4/23/2007 Outperform NS $637.27 -99.94% +112.88% -212.83 0 Comment
TrackCantorFitz 42.20 4/10/2007 Outperform NS $653.61 -99.94% +119.10% -219.05 0 Comment